Serum and urinary profile of bone turn-over markers in a patient with tamoxifen-induced hypercalcaemia submitted to pamidronate therapy
暂无分享,去创建一个
L. Dogliotti | A. Berruti | A. Piovesan | A. Angeli | M. Torta | P. Sperone
[1] I. Henderson,et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. , 1993, The American journal of medicine.
[2] L. Dogliotti,et al. Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases. , 1993, Oncology.
[3] J. Ratcliffe,et al. Parathyroid hormone related protein and hypercalcaemia in breast cancer. , 1991, BMJ.
[4] J. Kanis,et al. Rationale for the use of bisphosphonates in bone metastases. , 1991, Bone.
[5] D. W. Moss,et al. Biochemical prediction of response of bone metastases to treatment. , 1988, British Journal of Cancer.
[6] A. Buzdar,et al. Tamoxifen‐induced hypercalcemia in breast cancer , 1981, Cancer.